Peptide therapeutics for rare genetic metabolic diseases


Rhythm Therapeutics (NASDAQ: RYTM) is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.


Year Invested: 2010
Location: Boston, Mass.
Visit: www.rhythmtx.com

Recent News

June 14, 2018
Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity

June 1, 2018
Rhythm Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

May 14, 2018
Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results

Read More News

Associated Team Members

Neil Exter
Partner